PubRank

Marco Racchi

Author PubWeight™ 37.37‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci 2005 1.68
2 Neuronal ELAV proteins enhance mRNA stability by a PKCalpha-dependent pathway. Proc Natl Acad Sci U S A 2005 1.45
3 Activation of the Notch pathway in Down syndrome: cross-talk of Notch and APP. FASEB J 2005 1.07
4 Cognition enhancers between treating and doping the mind. Pharmacol Res 2008 1.05
5 High interleukin-10 production is associated with low antibody response to influenza vaccination in the elderly. J Leukoc Biol 2006 1.01
6 p53 at the crossroads between cancer and neurodegeneration. Free Radic Biol Med 2012 1.00
7 Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer's disease patients. J Cell Sci 2002 0.98
8 Phosphorylation of APP-CTF-AICD domains and interaction with adaptor proteins: signal transduction and/or transcriptional role--relevance for Alzheimer pathology. J Neurochem 2010 0.98
9 Differential involvement of protein kinase C alpha and epsilon in the regulated secretion of soluble amyloid precursor protein. Eur J Biochem 2004 0.95
10 In vitro and ex vivo antihydroxyl radical activity of green and roasted coffee. J Agric Food Chem 2004 0.94
11 Unfolded p53: a potential biomarker for Alzheimer's disease. J Alzheimers Dis 2007 0.91
12 Capillary electrophoresis studies on the aggregation process of beta-amyloid 1-42 and 1-40 peptides. Electrophoresis 2004 0.91
13 nELAV proteins alteration in Alzheimer's disease brain: a novel putative target for amyloid-beta reverberating on AbetaPP processing. J Alzheimers Dis 2009 0.90
14 Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients. Neurobiol Aging 2005 0.90
15 Unfolded p53 in the pathogenesis of Alzheimer's disease: is HIPK2 the link? Aging (Albany NY) 2010 0.89
16 Why do centenarians escape or postpone cancer? The role of IGF-1, inflammation and p53. Cancer Immunol Immunother 2009 0.89
17 CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity. Electrophoresis 2009 0.88
18 Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug ganstigmine (CHF-2819). J Med Chem 2006 0.88
19 In vivo dehydroepiandrosterone restores age-associated defects in the protein kinase C signal transduction pathway and related functional responses. J Immunol 2002 0.86
20 beta-Amyloid precursor protein metabolism: focus on the functions and degradation of its intracellular domain. Pharmacol Res 2010 0.86
21 Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? J Pain Res 2013 0.86
22 Fibroblast glutamate transport in aging and in AD: correlations with disease severity. Neurobiol Aging 2005 0.85
23 Conformational altered p53 as an early marker of oxidative stress in Alzheimer's disease. PLoS One 2012 0.85
24 Functional mapping of the promoter region of the GNB2L1 human gene coding for RACK1 scaffold protein. Gene 2008 0.84
25 Homeodomain interacting protein kinase 2: a target for Alzheimer's beta amyloid leading to misfolded p53 and inappropriate cell survival. PLoS One 2010 0.83
26 Conformationally altered p53: a putative peripheral marker for Alzheimer's disease. Neurodegener Dis 2008 0.83
27 Over-expression of amyloid precursor protein in HEK cells alters p53 conformational state and protects against doxorubicin. J Neurochem 2007 0.83
28 Acute beta-amyloid administration disrupts the cholinergic control of dopamine release in the nucleus accumbens. Neuropsychopharmacology 2007 0.83
29 Nicotinic component of galantamine in the regulation of amyloid precursor protein processing. Chem Biol Interact 2006 0.80
30 Influence of COMT Val158Met polymorphism on Alzheimer's disease and mild cognitive impairment in Italian patients. J Alzheimers Dis 2012 0.80
31 Expression and phosphorylation of delta-CaM kinase II in cultured Alzheimer fibroblasts. Neurobiol Aging 2004 0.80
32 Age-related decline in RACK-1 expression in human leukocytes is correlated to plasma levels of dehydroepiandrosterone. J Leukoc Biol 2004 0.80
33 Unfolded p53 in blood as a predictive signature signature of the transition from mild cognitive impairment to Alzheimer's disease. J Alzheimers Dis 2010 0.80
34 Role of PKC-β in chemical allergen-induced CD86 expression and IL-8 release in THP-1 cells. Arch Toxicol 2013 0.79
35 Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitors. Angew Chem Int Ed Engl 2014 0.78
36 Recruitment of casein kinase 2 is involved in AbetaPP processing following cholinergic stimulation. J Alzheimers Dis 2010 0.78
37 Opposing effects of cortisol and dehydroepiandrosterone on the expression of the receptor for Activated C Kinase 1: implications in immunosenescence. Exp Gerontol 2011 0.78
38 Mucoadhesive microspheres for nasal administration of cyclodextrins. J Drug Target 2009 0.78
39 Serotonin transporter polymorphism modifies the association between depressive symptoms and sleep onset latency complaint in elderly people: results from the 'InveCe.Ab' study. J Sleep Res 2014 0.77
40 Wild type but not mutant APP is involved in protective adaptive responses against oxidants. Amino Acids 2010 0.76
41 Dangerous liaisons between beta-amyloid and cholinergic neurotransmission. Curr Pharm Des 2014 0.76
42 Modulation of Rack-1/PKCβII signalling by soluble AβPPα in SH-SY5Y cells. Curr Alzheimer Res 2013 0.76
43 Zyxin is a novel target for β-amyloid peptide: characterization of its role in Alzheimer's pathogenesis. J Neurochem 2013 0.75
44 Development of the first Gateway firefly luciferase vector and use of reverse transcriptase in FLOE (Fluorescently Labeled Oligonucleotide Extension) reactions. Plasmid 2007 0.75
45 Searching for predictive blood biomarkers: misfolded p53 in mild cognitive impairment. Curr Alzheimer Res 2012 0.75
46 AβPP intracellular C-terminal domain function is related to its degradation processes. J Alzheimers Dis 2012 0.75
47 Do we need pharmacogenetics to personalize antidepressant therapy? Cell Mol Life Sci 2012 0.75